Johnson & Johnson to Separate Into Two Businesses

By

woman scientist and Johnson & Johnson
Image via Johnson & Johnson.

Johnson & Johnson will separate into two public companies, writes John George for the Philadelphia Business Journal.

One company will focus on consumer health products, while the other concentrates on pharmaceuticals and medical devices.

Johnson & Johnson is based in New Brunswick, NJ. Its local sites include a manufacturing plant in Fort Washington (where Tylenol, among other products, is made), a Spring House Janssen Research and Development campus, and Janssen Pharmaceuticals offices in Horsham.

The company generated $82.6 billion in revenue last year.

The company will spin off its consumer health business — which includes Tylenol, Band-Aids, Neutrogena, and Listerine — into a new publicly-traded company.

“Following a comprehensive review, the board and management team believe that the planned separation of the consumer health business is the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals; create opportunities for our talented global team; drive profitable growth; and — most importantly — improve health care outcomes for people around the world,” said Alex Gorsky, CEO of Johnson & Johnson.

Read more about Johnson & Johnson in the Philadelphia Business Journal.

Connect With Your Community

Subscribe for stories that matter!

"*" indicates required fields

Hidden
BT Yes
This field is for validation purposes and should be left unchanged.
Advertisement